Zimmer Biomet Rises As Citi Ups Rating On Price Nod To Lead HHS

Citi's Hazan upgraded Zimmer Biomet to Neutral from Sell, saying the selection of Tom Price to head Health and Human Services "all but ensures current bundled payment programs may be significantly diluted."